Research progress of icariin, an extract of traditional Chinese medicine, in the treatment of asthma
Author(s) -
Jia-ying Yuan,
Zhiying Tong,
Yuchao Dong,
Jiayi Zhao,
Yan Shang
Publication year - 2022
Publication title -
allergologia et immunopathologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.483
H-Index - 37
eISSN - 1578-1267
pISSN - 0301-0546
DOI - 10.15586/aei.v50i1.490
Subject(s) - icariin , medicine , asthma , epimedium , traditional chinese medicine , adverse effect , intensive care medicine , hormone , immune system , pharmacology , immunology , alternative medicine , pathology
Bronchial asthma is a common chronic airway disease, and long-term management of asthma is the focus and challenge of clinical treatment. Glucocorticoids are often used as the first choice for the treatment of asthma. However, the occurrence of hormone dependence, hormone resistance, and local and systemic adverse reactions caused by hormone application also creates problems for the treatment of asthma. Finding new, safe, and effective therapeutic drugs is an important research direction at present. Icariin is an effective ingredient of the traditional Chinese medicine, Epimedium. It has various biological attributes such as anti-inflammatory and antioxidative activities, and immune regulation. It has high safety and a wide range of clinical applications. Icariin has the characteristics of multitargeted intervention in the treatment of asthma. Here, we review the specific mechanisms of icariin in treating asthma, and icariin is considered a novel therapy in controlling asthma; however, the mechanism is still worth further investigation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom